Koo, I took the salary data from the AGM document sent prior to the meeting. Don't know how they are actually being paid but nobody is jumping ship so far. So that is good because there are good people in this company.

As far as Eversana goes as I've stated before their primary focus should be as follows;

1. They should be brand building within retail investors. The RVX science is full of great stories that will be of interest to large bases of investors in North America. It is extremely exciting science with many successes and building the retail share price will help.
2. They should be building RVX brand credibility and reputation with the medical and payer community at the appropriate time.
3. They should be using their network to create connections for financing BoM2 and the Covid trial.
4. They should manage the public face of RVX in order to restore credibility.
5. Perhaps if they have expertise in biotech financing (the Achilles heel of RVX) they should take on this role.

As far as forgetting about Don or not talking about him I'm not going to stop my criticism. We watched the AGM and it was the same old Pinocchio with the first twitch of his nose at the "Forward Looking Statement" where he set the stage for his big excuse page (slide 7). So the industry turn down was the only reason for RVX share price dropping from $0.84 to $0.25 in the past year??? Oh boy Pinocchoo....come on!

Lack of financing is the one central problem holding back RVX scientific progress and who is responsible for that........hint - the CEO who also holds the Presidents and COB positions!

GLTA

Toinv